



Merz Pharma announces new investment in Cytrellis Biosystems



Frankfurt am Main, and Boston, MA 27 April 2016 – Merz Pharma has made a strategic venture investment in Cytrellis Biosystems, a US based company developing a new class of non-surgical products to combat sagging skin associated with aging.

Cytrellis Biosystems, Inc.
Karen Cronholm,
Director of Strategic Marketing
655 Summer Street
Boston, MA 02210
USA
1 (857) 317-5191
kcronholm@cytrellis.com

Merz has joined a growing set of industry investors to back Boston-based Cytrellis Biosystems. The investment emphasizes Merz' strategy to allocate venture investment focused on the areas of anti-aging, skin rejuvenation and body shaping. And it's the latest example of Cytrellis' strategy to selectively attract investors who bring specific aesthetic industry expertise.

"As a young and innovative company with an experienced team, Cytrellis has the potential for a successful market launch of a revolutionary technology in the field of aesthetic medicine", said Hans-Jörg Bergler, Head of Global Corporate Development and member of the Merz Pharma Board. "For Merz, the investment in Cytrellis ideally fits our current venture strategy, which is dedicated to aesthetics"

Cytrellis is a Boston based, clinical stage company that has been developing an entirely new category of medical devices for the aesthetics market. Cytrellis' key proprietary technology removes excess skin without invasive surgery or scarring. This technology will enable physicians to improve sagging skin associated with aging on the face and other areas of the body and thereby address one of the aesthetic industry's largest unmet needs and most valuable opportunities.

"We're delighted to have Merz as a strategic investor," Doug Levinson, CEO and co-founder of Cytrellis. "From the outset, we've sought to selectively engage investors that can extend Cytrellis' access to aesthetics industry expertise. This investment from Merz allows us to achieve this goal. Merz has a remarkable depth of overall industry expertise in the global aesthetics market, and a wealth of medical device experience gained through the successful launches of Ultherapy® and Cellfina™."

In June 2015, Merz announced plans to fund investments in the global aesthetics market through corporate venture capital. "The global aesthetics market is growing fast and continues to present attractive investment opportunities for promising technologies to bring real benefit to patients and physicians," says Bergler.

PRESS RELEASE



The allocation of venture capital in cooperation with other investment partners is part of the long-term innovation and growth strategy of Merz. Through the acquisitions of Neocutis, Anteis and BioForm Medical, Merz has substantially expanded its presence in the aesthetics space in recent years. Most recently, the acquisition of Ulthera, with its advanced ultrasound technology platform, has accelerated Merz's growth in aesthetics and enhanced the company's ability to provide innovative treatments along the full continuum of care.

For more information about Merz's Corporate Venture Capital Fund, please visit www.merz.com/ventures-partnering.

About Merz Pharma Group

Merz is a privately held pharmaceutical company based in Frankfurt, Germany, with 36 subsidiaries in Europe, North America, Latin America and the Asia Pacific region. The company is active in research, development and distribution of innovative products in the areas of aesthetic medicine and neurologically induced movement disorders.

In the Aesthetics segment Merz offers a balanced portfolio of products for minimally invasive treatments. With the dermal fillers Radiesse, Belotero, Glytone as well as the Neocutis line of anti-aging skincare, the company is a major player in the global Aesthetics market. With the acquisition of Ulthera in mid-2014, we supplemented our offerings with ultrasound technology for non-invasive skin tightening and rejuvenation. For the treatment of neurologically induced movement disorders, Merz developed the first botulinum toxin free of complex proteins.

With its tetesept and Merz Spezial® brands, Merz Consumer Care is the leading provider of OTC medication, dietary supplements and skincare products in the German-speaking countries.

The Merz Pharma Group employs 2,754 people worldwide. The Company generated revenue of EUR 1,157.0 million in fiscal year 2014/15 (previous year: EUR 994.0 million).

About Cytrellis Biosystems

Cytrellis Biosystems, Inc. is a clinical stage medical technology company developing a new, proprietary class of aesthetic devices. Our devices are designed to remove sagging skin associated with aging without surgery or scarring, enabling aesthetic practitioners an unprecedented ability to improve age related changes in skin and restore youthful beauty. Cytrellis is dedicated to working with leading physicians and partners to develop unique product solutions, which emphasize safety, clinical results and improved quality of life. For more information about Cytrellis Biosystems, please visit www.cytrellis.com

Press contacts:

Cytrellis Biosystems
Karen Cronholm
Director of Strategic Marketing
655 Summer Street
Boston, MA 02210
USA
Email: kcronholm@cytrellis.com
Tel: 1 857 317 5191